Comerica Bank Buys New Shares in Evolus, Inc. (NASDAQ:EOLS)

Comerica Bank purchased a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 28,301 shares of the company's stock, valued at approximately $312,000.

Other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in Evolus by 63.5% during the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company's stock worth $2,753,000 after buying an additional 65,972 shares in the last quarter. KBC Group NV purchased a new position in Evolus during the 4th quarter worth $49,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Evolus by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock worth $148,000 after acquiring an additional 1,291 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Evolus by 2.2% in the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock valued at $885,000 after purchasing an additional 1,762 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Evolus by 9.8% in the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock valued at $368,000 after purchasing an additional 2,989 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Trading Up 0.6%

Shares of Evolus stock traded up $0.06 during midday trading on Tuesday, reaching $9.96. 801,849 shares of the company's stock traded hands, compared to its average volume of 688,183. The stock has a 50 day moving average of $11.25 and a 200-day moving average of $12.26. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82. The company has a market cap of $642.18 million, a PE ratio of -10.94 and a beta of 1.11. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Insider Activity at Evolus

In other news, Director Karah Herdman Parschauer sold 12,888 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the sale, the director now owns 32,183 shares in the company, valued at $418,057.17. This represents a 28.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Moatazedi sold 6,251 shares of the business's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now owns 508,619 shares of the company's stock, valued at approximately $6,306,875.60. The trade was a 1.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 86,241 shares of company stock worth $1,048,666 over the last 90 days. 5.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on EOLS. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Thursday, May 8th. BTIG Research initiated coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. Finally, Barclays lifted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus has a consensus rating of "Buy" and a consensus price target of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.